About the cutaneous targets of bexarotene in CTCL patients.

About the cutaneous targets of bexarotene in CTCL patients.

Exp Dermatol. 2010 Aug;19(8):e299-301

Authors: Knol AC, Quéreux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, Dréno B

Abstract
There are several approved therapies for cutaneous T-cell lymphoma (CTCL). The retinoids are one of the major biologic response modifiers used in CTCL, producing good response rates but few complete responses. Bexarotene has been demonstrated to act on malignant T-cells by inducing their apoptosis, but nothing is known about its role on keratinocytes and Langerhans cells. Immunohistochemical analysis using CD1a, HLA-DR, ICAM-1 (activation markers), CD95 and CD40 (apoptosis markers) was conducted on frozen sections of bexarotene-exposed cutaneous explants and skin biopsy specimens from patients treated with bexarotene. None of the studied markers was significantly modulated both on cutaneous explants and on skin biopsy specimens after treatment with bexarotene, compared to controls. Langerhans cells and keratinocytes do not appear to play a central role in the therapeutic control of CTCL by bexarotene therapy. The main bexarotene’s target thus remains T-cells by inducing their apoptosis, a mechanism that is different from the other retinoids used in CTCL.

PMID: 19845753 [PubMed – indexed for MEDLINE]

This entry was posted in Exp Dermatol and tagged . Bookmark the permalink.